Companies › Harmony Biosciences Management
2 active drug programs in 5 registered trials: 3 Phase 3, 1 Phase 2, 1 Phase 1; Other, Neurology, Psychiatry; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pitolisant (HBS-301) Histamine H3 receptor inverse agonist | HRH3 | Phase 3 | Prader-Willi Syndrome; Idiopathic Hypersomnia; EDS; Autism Spectrum Disorder | Apr 2027 |
| HBS-104 | – | Phase 1 | Sleep Deprivation | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05953389 | Pitolisant (HBS-301) | Phase 2 | Autism Spectrum Disorder | Psychiatry | Oct 2025 |
| NCT07848659 | HBS-104 | Phase 1 | Sleep Deprivation | Other | Feb 2027 |
| NCT06366464 | Pitolisant (HBS-301) | Phase 3 | Prader-Willi Syndrome | Other | Apr 2027 |
| NCT07500090 | Pitolisant (HBS-301) | Phase 3 | Idiopathic Hypersomnia | Neurology | Oct 2027 |
| NCT07675135 | Pitolisant (HBS-301) | Phase 3 | EDS | Neurology | Oct 2027 |
Novadip Biosciences Nanjing Minova Pharmaceutical Pharmazz Ensysce Biosciences Vigonvita Life Sciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.